BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[EMEA accepts Schering-Plough's schizophrenia drug Sycrest for review]]>http://www.bloggingstocks.com/2009/06/02/emea-accepts-schering-ploughs-schizophrenia-drug-sycrest-for-re/http://www.bloggingstocks.com/2009/06/02/emea-accepts-schering-ploughs-schizophrenia-drug-sycrest-for-re/http://www.bloggingstocks.com/2009/06/02/emea-accepts-schering-ploughs-schizophrenia-drug-sycrest-for-re/#commentsFiled under:

This morning, Schering-Plough (NYSE: SGP) announced that the European Medicines Agency (EMEA) acccepted for review the company's Marketing Authorisation Application for asenapine. If approved, it will be sold as Sycrest in the form of a tablet for the treatment of schizophrenia and manic episodes associated with bipolar I disorder.

Currently, the U.S. Food and Drug Administration is reviewing a new-drug application for asenapine under the brand name Saphris.

SGP noted that it "highlighted asenapine as one of the Five Stars in our late-stage research and development pipeline at our R&D Update meeting in November 2008. At that time, we said that our aspirational filing date for asenapine in Europe was in 2009."

Continue reading EMEA accepts Schering-Plough's schizophrenia drug Sycrest for review

EMEA accepts Schering-Plough's schizophrenia drug Sycrest for review originally appeared on BloggingStocks on Tue, 02 Jun 2009 10:20:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>asenapineinthenewspharmaceuticalsSchering-PloughschizophreniaSGPSycrestTue, 02 Jun 2009 10:20:00 EST